Literature DB >> 8580398

Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans.

S C Mehta1, D R Lu.   

Abstract

Sodium mercaptoundecahydrododecaborate or BSH is an important compound for boron neutron capture therapy (BNCT). The total clearance and steady state volume of distribution of BSH in humans and in laboratory animals were analyzed as a function of species body weight using the allometric equation for interspecies scaling. Significant linear relationships were obtained between log CLt (Lh-1) and log W (kg) (r = 0.972; p = 0.028) as well as log VSS (L) and log W (kg) (r = 0.999; p = 0.0005). The corresponding allometric equations were CLt = 0.127 W0.68 and VSS = 1.557 W0.87, respectively. BSH clearance in various species was shown to be a constant fraction (0.26) of creatinine clearance, the relationship being independent of body weight. Thus BSH clearance in various species occurred at similar pace when measured by a physiological parameter (creatinine clearance) rather than chronological time. Interspecies scale-up of plasma concentration-time data for the four species using a complex Dedrick plot resulted in similar profiles. Our results indicate that the BSH data obtained in laboratory animals could be utilized to generate preliminary estimates of the pharmacokinetic parameters in humans. These parameters can serve as guidelines for better planning of clinical studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8580398     DOI: 10.1002/bdd.2510160904

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  10 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Targeted drug delivery for boron neutron capture therapy.

Authors:  S C Mehta; D R Lu
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 3.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

4.  Interspecies scaling: predicting clearance of anticancer drugs in humans. A comparative study of three different approaches using body weight or body surface area.

Authors:  I Mahmood
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Jul-Sep       Impact factor: 2.441

5.  Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961).

Authors:  K Hideghéty; W Sauerwein; K Haselsberger; F Grochulla; H Fankhauser; R Moss; R Huiskamp; D Gabel; M de Vries
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

6.  Fractal volume of drug distribution: it scales proportionally to body mass.

Authors:  V Karalis; L Claret; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  A Simple Method for the Prediction of Human Concentration-Time Profiles and Pharmacokinetics of Antibody-Drug Conjugates (ADC) from Rats or Monkeys.

Authors:  Iftekhar Mahmood
Journal:  Antibodies (Basel)       Date:  2022-06-14

8.  Pharmacokinetics of sodium borocaptate: a critical assessment of dosing paradigms for boron neutron capture therapy.

Authors:  Christopher R Gibson; Alfred E Staubus; Rolf F Barth; Weilian Yang; Amy K Ferketich; Melvin M Moeschberger
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

Review 9.  Estimating xenobiotic half-lives in humans from rat data: influence of log P.

Authors:  J G Sarver; D White; P Erhardt; K Bachmann
Journal:  Environ Health Perspect       Date:  1997-11       Impact factor: 9.031

10.  Use of bile correction factors for allometric prediction of human pharmacokinetic parameters of torcetrapib, a facile cholesteryl ester transfer protein inhibitor.

Authors:  Ramesh Mullangi; Preeti Ahlawat; Ravi K Trivedi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.